[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xeris Pharmaceuticals Inc (XERS)

Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Xeris Pharmaceuticals Inc 1375 West Fulton Street Suite 1300 Chicago IL 60607 USA

www.xerispharma.com Employees: 435 P: 844-445-5704

Sector:

Medical

Description:

Xeris Biopharma Holdings is a biopharmaceutical company. It involved in developing and commercializing therapies for patient in endocrinology, neurology and gastroenterology. The company's principal product includes Gvoke(R), a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis(R), the first and only FDA-approved therapy for primary periodic paralysis. Xeris Biopharma Holdings, formerly known as Xeris Pharmaceuticals Inc., is headquartered in Chicago, IL.

Key Statistics

Overview:

Market Capitalization, $K 1,567,952
Enterprise Value, $K 1,677,252
Shares Outstanding, K 182,320
Float, K 174,389
% Float 95.65%
Short Interest, K 9,221
Short Float 5.06%
Days to Cover 6.75
Short Volume Ratio 0.45
% of Insider Shareholders 4.35%
% of Institutional Shareholders 42.75%

Financials:

Annual Sales, $ 291,850 K
Annual Net Income, $ 550 K
Last Quarter Sales, $ 92,100 K
Last Quarter Net Income, $ -31,100 K
EBIT, $ 47,430 K
EBITDA, $ 63,500 K

Growth:

1-Year Return 10.68%
3-Year Return 259.83%
5-Year Return 290.91%
5-Year Revenue Growth 1,327.84%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.00 on 08/06/26
Next Earnings Date 11/05/26
Earnings Per Share ttm 0.07
EPS Growth vs. Prev Qtr -100.00%
EPS Growth vs. Prev Year 100.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

XERS Ratios

Ratio
Price/Earnings ttm 119.00
Price/Earnings forward 119.00
Price/Earnings to Growth N/A
Return-on-Equity % 338.21%
Return-on-Assets % 3.50%
Profit Margin % 0.19%
Debt/Equity -25.96
Price/Sales 5.20
Price/Cash Flow 83.16
Price/Book N/A
Book Value/Share -0.06
Interest Coverage -1.02
60-Month Beta 0.66
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.